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Summary. The p53 gene is located on the short arm of 
chromosome 17. It encodes a 53-kd nuclear protein 
(p53) found in scant amounts in normal tissue. 
Mutations of the p53  gene have been reported in 
different human tumours. In breast cancer, it has been 
noted that the overexpression of p53 protein in the 
nucleus is an indicator of poor prognosis, although there 
is a high degree of variability, which may be due to 
different immunohistochemical techniques, varying 
assessment of results and the type of monoclonal 
antibody used. 
This study is an immunohistochemical analysis of 
p53 expression in 192  cases of infiltrating ductal 
carcinoma of the breast, correlating i t  with 
clinicopathological factors and the clinical course of the 
disease. 
Of al1 the breast-cancer tissue analysed, stains for 
p53 antibody were found in 87 tumours (45.3%). The 
results of multivariate analysis show that the independent 
predictors related to recurrence are tumour size, lymph- 
node metastasis and p53, while those related to death are 
necrosis, lymph-node metastasis and p53. 
In summary, our  ser ies  showed prognostic 
significance between the expression of p53 and shorter 
survival time and disease-free interval for al1 patients in 
general as well as those who presented lymph-node 
metastases at the time of diagnosis. 
Key words: p53, Immunohistochemical,  Ductal 
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lntroductlon 
Breast carcinoma is the most frequent malignant 
tumour in women (Tarragona, Spain: 26.1%). Despite 
advances in hormone treatment and chemotherapy, the 
rnortality rate has not diminished. It would be interesting 
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to carry out further studies to find prognostic factors 
which could help us predict the patient's clinical 
outcome, such as the relationship between the classical 
prognostic factors (i.e., tumour size, differentiation 
degree, histological type, lymph-node metastases) and 
new ones, because histology alone cannot always predict 
the clinical course of the disease due to the high degree 
of subjectivity involved. It has therefore become 
essential to look at the expression of different factors to 
determine prognostic groups (Bacus et al., 1989). 
The  p53  gene is  located on the short arm of 
chromosome 17. It encodes a 53-kd nuclear protein 
(p53) found in scant amounts in normal tissue. Through 
the synthesis of this protein, the gene exerts an inhibitory 
effect on cell proliferation and transformation (Lane and 
Benchimol, 1990; Ostrowski et al., 1991; Weinberg, 
1991), and controls the initiation andlor regulation of 
DNA replication, a s  well as  the transcription and 
regulation of the response to DNA alteration (Levine et 
al., 1991; Marshall, 1991) and programmed cell death 
(Hollstein et al., 1991; Montenarh, 1992; Dutta et al, 
1993). Mutations of the p53 gene have been reported in 
different human tumours (Nigro et al., 1989). Such 
mutations favour the expression of more stable, 
nonfunctioning mutant forms of the protein with a longer 
half-life, which accumulate in the nucleus and can be 
detected by immunohistochemistry (Iggo et al., 1990; 
Jaros et al., 1992). There is a correlation between the 
detection of mutations by molecular biology methods, 
like single-strand conformation polymorphism (SSCP), 
and the detection of the protein by immunohisto- 
chemistry (Varley et al., 1991; Thor et al., 1992; 
Andersen et al., 1993; Marchetti et al., 1993; Bhargava 
et al., 1994; Fisher et al., 1994; Hurlimann et al., 1994). 
This study is an immunohistochemical analysis of 
p53 expression in 192  cases of infiltrating ductal 
carcinoma of the breast, correlating it with clinicopatho- 
logical factors and the clinical course of the disease. 
Materials and methods 
A total of 1 9 2  patients with invasive breast 
p53 and breast cancer 
carcinoma were studied in the Verge de la Cinta Hospital 
in Tortosa from 1981 to 1992. Fresh tissue from biopsy 
or  tumourectomy was received in the Pathology 
Department immediately after surgical removal. It was 
fixed in buffered formalin for up to 18 hours and then 
embedded in paraffin. 
Clinical study 
Conventional clinical features were evaluated, 
including age, menstrual status, treatment carried out, 
complementary treatment, presence of metastases (local 
and distant) and patient death (distinguishing between 
death from breast cancer and other causes). Follow-up 
information was extracted from patients' charts or, if a 
patient died, by correspondence with the hospital and 
attending physician at the time of death. 
Histopathological characteristics 
Histopathological characteristics were studied in 
sections stained with haematoxylin-eosin. The  
histological grade was determined according to criteria 
established by Bloom and Richardson (1957), modified 
by Elston (1988), and histological type according to the 
WHO classification (1981). 
Classic pathological features were evaluated, 
including tumour size, tumour necrosis and node 
metastases. Tumour size (in mm). Tumour necrosis, 
depending on whether or not there was necrosis in the 
infiltrating component of the carcinoma. Presence or 
absence of lymph-node metastasis and, if present, the 
number of nodes involved. 
Immunohistochemical study 
The methodology previously described (Sirvent et 
al., 1995) was used to determine p53 protein. The 
protein was assessed according to the intensity of 
staining (1), with values from O to 2, and the number of 
positive cells (P) was quantified as  1 when the 
percentage was from 1 to 24%, 2 at 25-49% positive 
cells, 3 at 50-74% positive cells, and 4 at 75-100% 
positive cells. A histological score was calculated by the 
formula, 1 x P; the range was from O to 8 (no values of 5 
or 7 were recorded). 
Statistical analysis 
Descriptive analysis: The  mean, the standard 
deviation (SD) and minimum and maximum values were 
used for quantitative variables. Categorical variables 
were described in terms of absolute and relative 
frequency. 
Survival analysis: Survival curves were calculated 
for recurrence and death using the Kaplan-Meier 
method. 
Predictive-factor analysis: Recurrence and death 
were used as independent variables. 
Univariate analysis: The Cox proportional-risk 
analysis was used to calculate the relative risk (RR) of 
the different predictive variables. A 95% confidence 
interval(95% CI) was calculated for each RR. 
Multivariate analysis: The Cox proportional-risk 
analysis was used to evaluate the independent predictive 
variables after they were adjusted. The results are given 
as RR with a 95% CI. 
The accepted leve1 of statistical significance was 
pe0.05. 
Data analysis was carried out using the BMDP 
package of statistical programs (Dixon, 1991). 
Results 
Clinical and histological findings 
Patient characteristics are shown in Table 1. The 
mean age at diagnosis in this series was 60 years (SD 
12.9) (range, 27-90). Menstrual status was known in 179 
of the 192  patients,  of whom 152  (84.9%) were 
postmenopausal (12 months or more since the last 
menstruation). 
Table 1. Clinical, histological and immunohistochemical findings. 
Menopausal status 
Premenopausal women 
Postmenopausal women 
Unknown 
Turnour size 
r 20 mm 
21 -50 
>50 
Unknown 
Histological grade 
I 
I I 
111 
Unknown 
Tumour necrosis 
Presence 
Absence 
Unknown 
Lymph-node status 
Negative 
Positive 
1-3 
> 3 
Unknown 
Positive (1 -8) 
1 
2 
3 
4 
6 
8 
Negative 
p53 and breast cancer 
Histological grade 1 tumours were more common 
(47.6%) than grades 11 and 111 (38.6% and 13.7%, 
respectively). The mean tumour size was 3 cm (range, 
0.3-11 cm). Tumour necrosis was seen in 57 cases 
(30.6%). Of the 157 cases in which the axillary nodes 
could be analysed, 85 (54.1%) presented metastases in a 
varying number of nodes, ranging from 3 to 37. 
Specific staining was confined exclusively to the 
nuclei, showing different degrees of intensity and 
different numbers of positive cells (Figs. 1-4); it was 
observed exceptionally in the cytoplasm of cells 
undergoing mitosis (Fig. 2). Stains for p53 antibody 
were found in 87 tumours (45.3%) (Table 1). 
Clinical outcome 
The median follow-up for mortality was 61.5 months 
(95 % CI: 56.7-70.7) and for relapse was 51.9 (95% CI: 
37.1-60.8) during which time there were 55 deaths 
resulting from breast cancer. Disease-specific survival 
analyses were based on deaths resulting from breast 
cancer, leading us to censor the survival time of 16 
patients because of "death due to other causes". The 
number of relapses was 79 cases. 
The disease-free interval was 84% at one year (95% 
CI: 78.6-90.1) and 59.6% at five years (95% CI: 49.0- 
70.0). Survival time was 96% at one year (95% CI: 93.0- 
99.0) and 74.1% at five years (95% CI: 65.0-82.0). 
The relapse and overall survival curves for p53 and 
lymph nodes are shown in Figs. 5A, 5B, 6A and 6B. 
Table 2 gives the results of the univariate analysis. In 
the case of tumour recurrence, statistically significant 
predictors were age, tumour size, necrosis, lymph-node 
metastasis and p53. Age, tumour size, degree of 
differentiation, necrosis, lymph-node metastasis and p53 
were significantly related to death. 
The results of the multivariate analysis (Table 3) 
show that the independent predictors related to 
recurrence are tumour size, lymph-node metastasis and 
p53, while those related to death were necrosis, lymph- 
node metastasis and p53. Moreover, in the node-positive 
group, p53 was an independent indicator for disease-free 
interval and overall survival as well. It does not act as an 
Fig. 1. p53. Strong positive expression in nearly al1 cells (histoscore 8). ABC, x 250 
p53 and breast cancer 
independent prognostic variable in patients who are 
node-negative and p53-positive. The significance of p53 
becomes evident when we compare negative cases with 
those expressing some degree of positivity, whatever the 
histoscore may be. 
Discussion 
In histochemical studies the p53 protein is found in 
the ceil nucleus where the mutated protein clusters. On 
rare occasions we observed cytoplasmic positivity in 
Table 2. Univariate analysis in operable breast-cancer patients: Cox 
proportional-risk analysis. 
some cells undergoing mitosis, when the nuclear 
membrane was ruptured. 
In our work we found p53 protein, to a greater or 
lesser extent, in 45.3% of the cases, a figure that falls 
within the values published in the literature, which range 
from 11 to 58% (Friedrichs et al., 1993; Lipponen et al, 
1993; Martinazzi et al., 1993; Charpin et al., 1995; 
Gohring et al., 1995; Rosanelli et al., 1995; Rosen et al., 
1995; Sirvent et al., 1995; Horne et al, 1996; Katoh et 
al., 1996). 
This variability in results may be due to different 
Table 3. Multivariate analysis in operable breast-cancer patients: Cox 
proportional-risk analysis 
RECURRENCE SURVIVAL 
RR (95% CI) RR (95% CI) 
RECURRENCE SURVIVAL 
RR (95% CI) RR (95% CI) 
Age 
Tumour size 
Histological grade 
Necrosis 
Lymph-node status 
p53 stain 
Age 1 .36 (0.95-1.99) 1.49 (0.96-2.29) 
Tumour size 1.95 (1.1 1-2.91) 1.25 (0.76-2.04) 
Histological grade 1 .O3 (0.73-1.45) 1.12 (0.75-1.68) 
Necrosis 1.1 7 (0.88-1 55) 1.52 (1.02-2.26) 
Lyrnph-node status 2.05 (1.46-2.88) 2.54 (1.633.99) 
p53 stain 1 .S9 (1.08-3.33) 1.84 (1.06-4.31) 
Flg. 2. p 
- ng mitosis are positive in the cytopiasm also. ABC, x 400 
p53 and breast cancer 
immunohistochemical techniques (Fisher et al., 1994). 
For example, a very important step is antigen recovery, 
which is done at an early stage and may be accomplished 
with enzymes or heat, using a microwave oven, pressure 
cooker, baby-bottle steriliser, etc. and immersing the 
preparations in citrate buffer @H 6). 
Another important aspect is the assessment of the 
immunohistochemical results. Some studies express the 
number of positive cells as a percentage, considering a 
case positive when the number of positive cells is above 
10% (Catoretti et al., 1988; Thor et al., 1992; Andersen 
et al., 1993). We preferred a semi-quantitative method, 
which recent studies have shown to give a very good 
correlation with the true mutation of a gene exon, 
especially at higher values (histoscores of 6 and 8) 
(Bartek et al., 1990; Fisher et al., 1994). Al1 cases 
showing more than two-thirds of the cells positive and 
with marked staining had a p53 mutation (Schmitt et al., 
1998). 
To determine the sensitivity and specificity of 
immunohistochemistry for the detection of p53, the 
literature contains various studies using techniques for 
detecting mutations of the different exons which ñnd a 
good correlation (Varley et al., 1991; Thor et al., 1992; 
Andersen et al., 1993; Marchetti et al., 1993; Fisher et 
al., 1994), although there are as many as 30% false 
positives and negatives (Sommer et al., 1992; Dunn et 
al., 1993; Lohmann et al., 1993; Sjogren et al., 1996). 
This may be due to more positive cases being detected 
by immunohistochemistry than by genetic study (false 
positives), or because nonsense mutations occur which 
therefore do not accumulate protein (false negatives). 
Another factor that may influence the results is the 
type of monoclonal antibody used. In our study we used 
the DO7 clone because the results were very good in 
tissue sections fixed in formalin and embedded in 
paraffin; there was also a very good correlation with the 
other most commonly used antibody (Pabl801) 
(Friedrichs et al., 1993; Jacquemier et al., 1994; Home et 
al., 1996). 
In our study, the presence of p53 protein proved to 
be o£ independent prognostic value for both recurrence 
and overall survival. Friedrichs et al. (1993) and Thor et 
al. (1992) - the latter with a much longer follow-up - also 
found that p53 is an independent prognostic factor. 
Sjogren et al. (1996) observed that patients expressing 
p53 have a shorter disease-free interval and survival 
time, although this author's results were not statistically 
Flg. 3. Cancerisation of a lobule. p53-protein ~xpression in tumour cellc. ABC, x 250 
p53 and breast cancer 
significant. variable in patients who are node-negative and p53- 
The p53 gene has also been shown to be an positive, although the prognosis is worse for relapse, 
independent prognostic factor in node-positive patients, especially at high values (histoscore > 6). Neither is it 
both for relapse and disease-free interval (MacGrogan et significant for overall survival. These findings contrast 
al., 1995). It does not act as an independent prognostic with some reported in the literature (Allred et al., 1993; 
Flg. 4. Only a few cells are positive (histoscore 1). ABC, x 400 
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Lymph-node negative 
Lymph-node positive 
0% 
O 12 24 M 48 60 72 M % 109 IZO 132 144 156 168 180 
unode -:%? 64 44 m o n t h . 9  16 
nnodc+:85 71 34 12 A 
Fig. 6. A,B. Relapse and overall survival cuives for lymph nodes. 
Silvestrini et al., 1993, 1996). 
In summary, our series showed prognostic 
significance between the expression of p53 and shorter 
survival time and disease-free interval for al1 patients in 
general as well as those who presented lymph-node 
metastases at the time of diagnosis. 
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